Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.2K
Overview
31.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.

Nature·2026
Same author

Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires.

PloS one·2026
Same author

Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.

JAMA·2026
Same author

Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters.

The Lancet. Infectious diseases·2026
Same author

Author Correction: Long COVID involves activation of proinflammatory and immune exhaustion pathways.

Nature immunology·2026
Same author

Utility of the US Preventive Services Task Force for Preeclampsia Risk Assessment and Aspirin Prophylaxis.

Obstetrical & gynecological survey·2026

Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.2K

Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.

Ninaad Lasrado1, Ai-Ris Y Collier1, Nicole P Hachmann1

  • 1Beth Israel Deaconess Medical Center, Boston, MA, USA.

Vaccine
|October 23, 2023
PubMed
Summary
This summary is machine-generated.

The new SARS-CoV-2 BA.2.86 variant shows reduced neutralizing antibody (NAb) titers compared to BA.2. However, NAb titers against BA.2.86 are comparable to other circulating variants, supporting the use of XBB.1.5 boosters.

Keywords:
BA.2.86Neutralizing antibodySARS-CoV-2VaccinemRNA

More Related Videos

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

1.7K

Related Experiment Videos

Last Updated: Jul 12, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.2K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

1.7K

Area of Science:

  • Virology
  • Immunology
  • Epidemiology

Background:

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continually evolves, leading to new variants.
  • The BA.2.86 variant possesses numerous spike protein mutations, raising concerns about immune evasion.

Purpose of the Study:

  • To assess the impact of SARS-CoV-2 BA.2.86 variant mutations on neutralizing antibody (NAb) titers.
  • To compare the immunogenicity of BA.2.86 against other circulating SARS-CoV-2 variants.

Main Methods:

  • Quantification of neutralizing antibody (NAb) titers against SARS-CoV-2 variants.
  • Comparison of NAb responses in vaccinated individuals with and without prior XBB.1.5 infection.

Main Results:

  • NAb titers against BA.2.86 were significantly lower than against BA.2.
  • NAb titers against BA.2.86 were similar or higher compared to XBB.1.5, EG.5.1, and FL.1.5.1.
  • Vaccinated individuals with a history of XBB.1.5 infection exhibited higher NAb titers against all tested variants.

Conclusions:

  • The BA.2.86 variant exhibits partial immune escape from neutralizing antibodies.
  • Monovalent XBB.1.5 mRNA boosters may offer cross-protection against current and emerging SARS-CoV-2 variants.